Glycoprotein IIb/IIIa inhibitors and bivalirudin in patients undergoing percutaneous coronary intervention
Glycoprotein IIb/IIIa inhibitors and bivalirudin in patients undergoing percutaneous coronary intervention
Percutaneous coronary intervention (PCI) is currently the standard of care for patients presenting with acute coronary syndrome (ACS), as well those patients with "stable" angina who have failed medical therapy in whom PCI is an acceptable alternative to surgical revascularization. The aim of adjunctive antiplatelet and antithrombotic therapy during PCI is to alleviate the risks associated with platelet activation and aggregation, iatrogenic plaque rupture, and thrombus formation during. The aim of this review is to summarize the evidence that has emerged from the randomized studies comparing a strategy combining heparin and a glycoprotein IIb/IIIa inhibitor (GPI) with that of bivalirudin in patients undergoing elective and urgent PCI.
95-100
Mahmoudi, M.
1dfae087-fe15-4e03-9f1a-510a4a84a6d5
Waksman, R.
a5540f63-dc45-4bf1-bc19-21362a713739
February 2012
Mahmoudi, M.
1dfae087-fe15-4e03-9f1a-510a4a84a6d5
Waksman, R.
a5540f63-dc45-4bf1-bc19-21362a713739
Mahmoudi, M. and Waksman, R.
(2012)
Glycoprotein IIb/IIIa inhibitors and bivalirudin in patients undergoing percutaneous coronary intervention.
Minerva Cardioangiologica, 60 (1), .
(PMID:22322577)
Abstract
Percutaneous coronary intervention (PCI) is currently the standard of care for patients presenting with acute coronary syndrome (ACS), as well those patients with "stable" angina who have failed medical therapy in whom PCI is an acceptable alternative to surgical revascularization. The aim of adjunctive antiplatelet and antithrombotic therapy during PCI is to alleviate the risks associated with platelet activation and aggregation, iatrogenic plaque rupture, and thrombus formation during. The aim of this review is to summarize the evidence that has emerged from the randomized studies comparing a strategy combining heparin and a glycoprotein IIb/IIIa inhibitor (GPI) with that of bivalirudin in patients undergoing elective and urgent PCI.
This record has no associated files available for download.
More information
Published date: February 2012
Organisations:
Human Development & Health
Identifiers
Local EPrints ID: 395390
URI: http://eprints.soton.ac.uk/id/eprint/395390
ISSN: 0026-4725
PURE UUID: 2c6876eb-eac2-4dda-8576-b75a9d08965f
Catalogue record
Date deposited: 08 Jul 2016 15:44
Last modified: 08 Jan 2022 03:31
Export record
Contributors
Author:
M. Mahmoudi
Author:
R. Waksman
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics